CA1314876C - Azithromycin dihydrate - Google Patents

Azithromycin dihydrate

Info

Publication number
CA1314876C
CA1314876C CA000571381A CA571381A CA1314876C CA 1314876 C CA1314876 C CA 1314876C CA 000571381 A CA000571381 A CA 000571381A CA 571381 A CA571381 A CA 571381A CA 1314876 C CA1314876 C CA 1314876C
Authority
CA
Canada
Prior art keywords
azithromycin
dihydrate
water
hydrocarbon
hygroscopic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000571381A
Other languages
English (en)
French (fr)
Inventor
Douglas John Meldrum Allen
Kevin Michael Nepveux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22202456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1314876(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Application granted granted Critical
Publication of CA1314876C publication Critical patent/CA1314876C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA000571381A 1987-07-09 1988-07-07 Azithromycin dihydrate Expired - Lifetime CA1314876C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US87/01612 1987-07-09
PCT/US1987/001612 WO1989000576A1 (en) 1987-07-09 1987-07-09 Azithromycin dihydrate

Publications (1)

Publication Number Publication Date
CA1314876C true CA1314876C (en) 1993-03-23

Family

ID=22202456

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000571381A Expired - Lifetime CA1314876C (en) 1987-07-09 1988-07-07 Azithromycin dihydrate

Country Status (45)

Country Link
US (1) US6268489B1 (cg-RX-API-DMAC7.html)
EP (1) EP0298650B1 (cg-RX-API-DMAC7.html)
JP (1) JPH0631300B2 (cg-RX-API-DMAC7.html)
KR (1) KR900006218B1 (cg-RX-API-DMAC7.html)
CN (1) CN1016785B (cg-RX-API-DMAC7.html)
AP (1) AP44A (cg-RX-API-DMAC7.html)
AR (1) AR243532A1 (cg-RX-API-DMAC7.html)
AT (1) ATE72446T1 (cg-RX-API-DMAC7.html)
AU (1) AU604553B2 (cg-RX-API-DMAC7.html)
BA (1) BA98213B1 (cg-RX-API-DMAC7.html)
BG (1) BG47348A3 (cg-RX-API-DMAC7.html)
CA (1) CA1314876C (cg-RX-API-DMAC7.html)
CS (1) CS272241B2 (cg-RX-API-DMAC7.html)
CY (1) CY1776A (cg-RX-API-DMAC7.html)
DD (1) DD271705A5 (cg-RX-API-DMAC7.html)
DE (1) DE3868296D1 (cg-RX-API-DMAC7.html)
DK (1) DK172573B1 (cg-RX-API-DMAC7.html)
EG (1) EG18527A (cg-RX-API-DMAC7.html)
ES (1) ES2038756T3 (cg-RX-API-DMAC7.html)
FI (1) FI91263C (cg-RX-API-DMAC7.html)
GR (1) GR3003737T3 (cg-RX-API-DMAC7.html)
HK (1) HK127594A (cg-RX-API-DMAC7.html)
HU (1) HU211862A9 (cg-RX-API-DMAC7.html)
IE (1) IE60354B1 (cg-RX-API-DMAC7.html)
IL (1) IL86979A (cg-RX-API-DMAC7.html)
IN (1) IN168879B (cg-RX-API-DMAC7.html)
IS (1) IS1540B (cg-RX-API-DMAC7.html)
LV (1) LV10624B (cg-RX-API-DMAC7.html)
MA (1) MA21323A1 (cg-RX-API-DMAC7.html)
MX (1) MX12213A (cg-RX-API-DMAC7.html)
MY (1) MY103744A (cg-RX-API-DMAC7.html)
NO (1) NO171556C (cg-RX-API-DMAC7.html)
NZ (1) NZ225338A (cg-RX-API-DMAC7.html)
OA (1) OA08743A (cg-RX-API-DMAC7.html)
PH (1) PH30953A (cg-RX-API-DMAC7.html)
PL (1) PL157145B1 (cg-RX-API-DMAC7.html)
PT (1) PT87933B (cg-RX-API-DMAC7.html)
RO (1) RO107257B1 (cg-RX-API-DMAC7.html)
RU (1) RU2066324C1 (cg-RX-API-DMAC7.html)
SG (1) SG27794G (cg-RX-API-DMAC7.html)
SI (1) SI8811325A8 (cg-RX-API-DMAC7.html)
UA (1) UA27040C2 (cg-RX-API-DMAC7.html)
WO (1) WO1989000576A1 (cg-RX-API-DMAC7.html)
YU (1) YU45075B (cg-RX-API-DMAC7.html)
ZA (1) ZA884925B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
US5912331A (en) * 1991-03-15 1999-06-15 Merck & Co., Inc. Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
US5985844A (en) * 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5189159A (en) * 1992-04-02 1993-02-23 Merck & Co., Inc. 8a-AZA-8a-homoerythromycin cyclic iminoethers
CA2081268A1 (en) * 1991-10-25 1993-04-26 Katsuhiro Imaki Glycine derivative monosodium salt tetrahydrate
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
US5210235A (en) * 1992-08-26 1993-05-11 Merck & Co., Inc. Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics
US5332807A (en) * 1993-04-14 1994-07-26 Merck & Co., Inc. Process of producing 8A- and 9A-azalide antibiotics
CN1034734C (zh) * 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
JP2977907B2 (ja) 1994-05-06 1999-11-15 ファイザー・インコーポレーテッド アジスロマイシンの放出調節された剤形
ES2122905B1 (es) * 1996-07-11 1999-11-16 Astur Pharma Sa Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
WO1999020639A2 (en) * 1997-10-16 1999-04-29 Pliva, Farmaceutska Industrija ,Dionicko, Drustvo NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
PT102130A (pt) * 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
US6245903B1 (en) 1998-08-21 2001-06-12 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
WO2000032203A1 (en) * 1998-11-30 2000-06-08 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
ATE392427T1 (de) * 1999-05-18 2008-05-15 Pfizer Prod Inc Neue kristalline formen eines macrolidantibiotikums
ES2267549T3 (es) 1999-06-29 2007-03-16 Sandoz Ag Procedimiento para la produccion de azitromicina.
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
ATE388159T1 (de) 2000-01-04 2008-03-15 Teva Pharma Verfahren zur herstellung von azithromycin- dihydrat
ES2162764B1 (es) * 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
CA2417353C (en) 2000-07-25 2009-09-01 Laboratorio Silanes,S.A. De C.V. Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-one, and obtaining a new form of 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin a
ES2172417B1 (es) * 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
CA2419873A1 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
CN100341886C (zh) * 2000-11-27 2007-10-10 桑多斯股份公司 大环内酯类化合物的溶剂化物
HU229488B1 (hu) * 2000-11-27 2014-01-28 Sandoz Ag Eljárás makrolid hidrátok elõállítására
IN190080B (cg-RX-API-DMAC7.html) * 2001-01-29 2003-06-07 Alembic Ltd
KR100491183B1 (ko) 2001-03-21 2005-05-25 한미약품 주식회사 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
JP2005501862A (ja) * 2001-08-21 2005-01-20 ファイザー・プロダクツ・インク １回限りの投与量のアジスロマイシン
BR0215193A (pt) * 2001-12-21 2004-11-16 Pfizer Prod Inc Formulações de azitromicina diretamente compressìveis
KR100669279B1 (ko) * 2001-12-21 2007-01-16 화이자 프로덕츠 인크. 아지트로마이신의 습식 제립 방법
EP1478347A1 (en) * 2002-02-01 2004-11-24 Pfizer Products Inc. Dry granulated formulations of azithromycin
US7376064B2 (en) 2002-02-25 2008-05-20 Samsung Electronics Co., Ltd. Method and apparatus for recording data on optical recording medium
ITMI20021209A1 (it) * 2002-06-04 2003-12-04 Chemi Spa Processo di preparazione di azitromicina ad elevata purezza
US6855813B2 (en) * 2002-07-19 2005-02-15 Alembic Limited Process for the preparation of azithromycin monohydrate
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
GB2395482A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Process for preparing non-hygroscopic azithromycin dihydrate
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
BRPI0417360A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
JP2007513139A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
RU2260012C1 (ru) * 2004-01-29 2005-09-10 Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" Способ кристаллизации азитромицина дигидрата
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2006011160A1 (en) 2004-06-28 2006-02-02 Alembic Limited Process for the preparation of azithromycin monohydrate isopropanol clathrate
CN1308361C (zh) * 2004-08-09 2007-04-04 大连振邦氟涂料股份有限公司 乙烯－三氟氯乙烯共聚物的制备方法
US7683162B2 (en) * 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
DE602005021684D1 (de) * 2004-12-01 2010-07-15 Teva Gyogyszergyar Zartkoeruen Verfahren zur herstellung von pimecrolimus
WO2006067576A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CN100366686C (zh) * 2006-01-12 2008-02-06 济南瑞氟化工科技有限公司 一种氟硅超双疏不粘涂料
AU2007256844A1 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
US7704959B2 (en) 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
US20090062220A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched azithromycin
CN101177441B (zh) * 2007-12-05 2012-05-23 浙江耐司康药业有限公司 一种稳定的阿奇霉素一水合物结晶的制备方法
CN101624412B (zh) * 2008-07-10 2012-07-04 刘力 大环内酯类衍生物及其制备和用途
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
CN101418026B (zh) * 2008-10-09 2011-05-18 南京工业大学 一种晶型和粒度可控的阿奇霉素结晶工艺
CN101787063B (zh) * 2009-01-23 2012-12-19 刘力 抗感染药物及其制备和用途
CN102413826A (zh) 2009-03-13 2012-04-11 达·沃尔泰拉公司 用于消除革兰氏阴性菌的组合物和方法
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
CN102911219A (zh) * 2011-08-03 2013-02-06 山东方明药业集团股份有限公司 一种阿齐霉素在水相直接结晶的方法
CN103159811A (zh) * 2011-12-10 2013-06-19 山东方明药业集团股份有限公司 一种阿齐霉素中间体9a-脱氧-9a-氮杂-9a-高红霉素A的制备方法
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
CN102417531B (zh) * 2011-12-20 2014-06-11 浙江国邦药业有限公司 一种阿奇霉素一水合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020270A (en) * 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
US4219641A (en) * 1979-06-14 1980-08-26 The Upjohn Company Process for preparing erythromycin succinate
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4526889A (en) * 1982-11-15 1985-07-02 Pfizer Inc. Epimeric azahomoerythromycin A derivative, intermediates and method of use
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
YU43402B (en) * 1985-03-04 1989-06-30 Pliva Pharm & Chem Works Process for preparation of 11-aza-10-deoxo-10-dihydroeritromycin "a" by using electro-chemical reduction
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation

Also Published As

Publication number Publication date
AP8800093A0 (en) 1988-05-01
AU604553B2 (en) 1990-12-20
EP0298650A2 (en) 1989-01-11
EG18527A (en) 1993-10-30
DE3868296D1 (de) 1992-03-19
PL273590A1 (en) 1989-03-20
NO900077D0 (no) 1990-01-08
EP0298650B1 (en) 1992-02-05
IS1540B (is) 1994-01-28
AU1883988A (en) 1989-01-12
US6268489B1 (en) 2001-07-31
NO900077L (no) 1990-01-08
CS272241B2 (en) 1991-01-15
JPH0631300B2 (ja) 1994-04-27
DK172573B1 (da) 1999-01-25
IN168879B (cg-RX-API-DMAC7.html) 1991-06-29
ES2038756T3 (es) 1993-08-01
JPS6438096A (en) 1989-02-08
UA27040C2 (uk) 2000-02-28
MY103744A (en) 1993-09-30
WO1989000576A1 (en) 1989-01-26
CN1030422A (zh) 1989-01-18
PL157145B1 (en) 1992-04-30
DK380688D0 (da) 1988-07-08
KR900006218B1 (ko) 1990-08-25
LV10624A (lv) 1995-04-20
GR3003737T3 (cg-RX-API-DMAC7.html) 1993-03-16
FI900087L (fi) 1990-01-08
LV10624B (en) 1995-10-20
RU2066324C1 (ru) 1996-09-10
BA98213B1 (bs) 1999-08-02
FI900087A0 (fi) 1990-01-08
IL86979A (en) 1992-11-15
NO171556B (no) 1992-12-21
NO171556C (no) 1993-03-31
FI91263C (fi) 1994-06-10
ZA884925B (en) 1990-02-28
YU132588A (en) 1990-02-28
DD271705A5 (de) 1989-09-13
SI8811325A8 (en) 1996-12-31
OA08743A (fr) 1989-03-31
IE882108L (en) 1989-01-09
YU45075B (en) 1991-08-31
MA21323A1 (fr) 1989-04-01
EP0298650A3 (en) 1989-11-08
KR890002137A (ko) 1989-04-08
PH30953A (en) 1997-12-23
FI91263B (fi) 1994-02-28
BG47348A3 (bg) 1990-06-15
PT87933A (pt) 1989-06-30
AP44A (en) 1989-07-27
NZ225338A (en) 1990-02-26
ATE72446T1 (de) 1992-02-15
SG27794G (en) 1994-10-14
RO107257B1 (ro) 1993-10-30
HU211862A9 (en) 1995-12-28
IS3370A7 (is) 1989-01-10
AR243532A1 (es) 1993-08-31
DK380688A (da) 1989-01-10
IL86979A0 (en) 1988-12-30
MX12213A (es) 1993-05-01
PT87933B (pt) 1994-09-30
IE60354B1 (en) 1994-06-29
CN1016785B (zh) 1992-05-27
CY1776A (en) 1995-10-20
CS489688A2 (en) 1990-03-14
HK127594A (en) 1994-11-25

Similar Documents

Publication Publication Date Title
CA1314876C (en) Azithromycin dihydrate
EP0041355B1 (en) Novel erythromycin compounds
HK586A (en) Oximes derived from erythromycin a, their preparation, their application in pharmaceuticals and pharmaceutical compositions containing them
CZ3597A3 (en) Process for preparing trihydrate of (2r,3s)-4-acetoxy-2alpha-benzoyl-oxy-5beta,20-epoxy-1,7beta,10beta-trihyd roxy-9-oxo-tax-11-ene-13alpha-yl-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate
RU2030416C1 (ru) Способ получения 23-(c1-c6-алкилоксимов)-ll-f-28249
US4464527A (en) Antibacterial 9-deoxo-9a-alkyl-9a-aza-9a-homoerythromycin A derivatives and intermediates therefore
GB2264944A (en) 2-amino-2,4,4-trimethylpentane salt of clavulanic acid
EP0503949A1 (en) Novel process for the preparation of 9-deoxo-9(z)-hydroxyiminoerythromycin A
KR100375957B1 (ko) D4t 동질이상 i 형의 제조방법
EP0503932A1 (en) 9-Deoxo-9(z)-hydroxy-iminoerythromycin A and O-derivatives thereof
EP0000656B1 (en) 4"-ureido-oleandomycin derivatives, process for their preparation and their use in pharmaceutical compositions
KR880001235B1 (ko) 결정성 무수 소듐 19-데옥시아글리콘 디아네마이신의 제조 방법
US5606039A (en) Etoposide phosphate and preparative intermediates
US6548692B1 (en) Method for preparing 1,2-dibromo-2,4-dicyanobutane
KR0137458B1 (ko) 암포테리신 b의 정제 방법 및 그를 위한 조성물
MXPA04010587A (es) [2r-(2r*, 3s*, 4r*, 5r*, 8r*, 10r*, 11r*, 2s*, 3s*, 14r*)]- 13-[(2 6-d deoxi-3-c- metil- -l- ribo- hexopiranosil) oxi]-2-etil-3], 4, 10- trihidroxi-3, 5, 6, 8, 10, 12, 14-heptametil- 11-[[3, 4, 6-trideoxi- 3-(dimetilamino)- -d-xilo-5 hexopiranosil] o
HU203763B (en) Process for producing azitromycin-dihydrate
EP0106231A1 (en) Process for the O-demethylation of aminoglycoside compounds
HU209599B (en) Process for preparing pgp2 alpha tris-(hydroxymethyl)-aminomethan-salt with precipitating crystallisation
MXPA98009308A (en) Derivatives of 3-descladinosa-2, 3-anhydroeritromic

Legal Events

Date Code Title Description
MKEX Expiry